Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Sales (2016 - 2025)

Lineage Cell Therapeutics' Return on Sales history spans 16 years, with the latest figure at 0.93% for Q4 2025.

  • For Q4 2025, Return on Sales rose 20.0% year-over-year to 0.93%; the TTM value through Dec 2025 reached 2.4%, down 44.0%, while the annual FY2025 figure was 4.35%, 240.0% down from the prior year.
  • Return on Sales reached 0.93% in Q4 2025 per LCTX's latest filing, roughly flat from 0.93% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.56% in Q4 2021 to a low of 9.7% in Q2 2021.
  • Average Return on Sales over 5 years is 3.02%, with a median of 2.15% recorded in 2022.
  • Peak YoY movement for Return on Sales: soared 1269bps in 2021, then plummeted -370bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 0.56% in 2021, then plummeted by -489bps to 3.3% in 2022, then soared by 32bps to 2.26% in 2023, then skyrocketed by 50bps to 1.13% in 2024, then grew by 18bps to 0.93% in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Return on Sales are 0.93% (Q4 2025), 0.93% (Q3 2025), and 6.99% (Q2 2025).